Advertisement

Chronic Daily Headache: Do We Know It When We See It?

  • Shweta Teckchandani
  • Robert Cowan
Chapter

Abstract

Chronic daily headache (CDH) is a category of headaches that affects 4% of the general population. While it does not have recognition in the current version of the International Classification of Headache Disorders (ICHD 3), it is a well-recognized clinical entity among headache specialists, and has been defined by Silberstein and Lipton as a headache lasting 15 or more days per month for at least three consecutive months. The majority of CDH is represented by transformed or chronic migraine (CM) and chronic tension-type headaches (CTTH). However, Hemicrania Continua (HC), Chronic Cluster (CC), and New Daily Persistent Headache (NDPH) are also included in this headache category (Headache Classification Committee of the International Headache Society (IHS), Cephalalgia. 33(9):629–808, 2013). Common comorbidities that are associated with CDH include medication overuse headaches, and psychiatric disorders such as depression, anxiety, and post-traumatic stress disorder (PTSD), as well as the myriad of comorbidities associated specifically with CM (Tzu-Hsien, Update of inpatient treatment for refractory chronic daily headache. Berlin: Springer Science; 2015). The best approach to treatment of CDH is a multidisciplinary one that includes medications, as well as non-pharmacologic therapies. Chronic daily headache remains a challenge for headache specialists and other clinicians, and accounts for more than 85% of the economic burden of headache on society (Soo-Jin, Outcome of chronic daily headache or chronic migraine. Berlin: Springer Science; 2015). Since there is no cure at this time, the goal of treatment remains reduction in the frequency, severity, and duration of headaches, with improvement in quality and function of life and reduced disability. This would create a positive economic impact on society through decreased costs and burden of disease.

Keywords

Headache Chronic migraine Tension-type Treatment Prophylaxis Botox Cluster 

References

  1. 1.
    Tzu-Hsien L. Update of inpatient treatment for refractory chronic daily headache. Berlin: Springer Science; 2015. Read by QxMD Icon Web. 07 May 2017Google Scholar
  2. 2.
    Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edn. (beta version). Cephalalgia. 2013;33(9):629–808.  https://doi.org/10.1177/0333102413485658.CrossRefGoogle Scholar
  3. 3.
    Lenaerts Marc EP, James R. Couch, Shweta Teckchandani, and Shuu-Jiun Wang. “Chronic daily headache”. Medlink Neurol. 2016.Google Scholar
  4. 4.
    Silberstein, S. D., et al. “Classification of Daily and near-Daily Headaches: Field Trial of Revised IHS Criteria.” Neurology. 1996;47(4):871–5.Google Scholar
  5. 5.
    Yancey J, Sheridan R, Koren KG. Chronic daily headache: diagnosis and management. Am Fam Physician. 2014;89(8):642–8.PubMedGoogle Scholar
  6. 6.
    Soo-Jin C. Outcome of chronic daily headache or chronic migraine. Berlin: Springer Science; 2015.Google Scholar
  7. 7.
    Murinova N, Krashin D. Chronic daily headache. Phys Med Rehabil Clin N Am. 2015;26(2):375–89.CrossRefPubMedGoogle Scholar
  8. 8.
    Volcy-Gomez M Chronic daily headache: I. Diagnosis and pathophysiology. Read by QxMD Icon. N.p., 2005, Curr Neurol Neurosci Rep. Mar 2001;1(2):118–24.Google Scholar
  9. 9.
    Cho SJ, Chu MK. Risk factors of chronic daile headache or chronic migraine. Curr Pain Headache Rep. 2015;19:465.CrossRefPubMedGoogle Scholar
  10. 10.
    Mercante JP, Peres MF, Guendler V, et al. Depression in chronic migraine: severity and clinical features. Arq Neuropsiquiatr. 2005;63(2A):217–20.CrossRefPubMedGoogle Scholar
  11. 11.
    Chiang CC, Schwedt TJ, Wang SJ, Dodick DW. Treatment of medication-overuse headache: a systematic review. Cephalalgia. 2015;36(4):371–86.CrossRefPubMedGoogle Scholar
  12. 12.
    Garza I, Schwedt TJ. Diagnosis and management of chronic daily headache. Semin Neurol. 2015;30(2):154–66.CrossRefGoogle Scholar
  13. 13.
    Bloudek LM. Cost of healthcare for patients with migraine in five European countries: results from the international burden of migraine study (IBMS). J Headache Pain. 2012;13(5):361–78.  https://doi.org/10.1007/s10194-012-0460-7. Published online 2012 May 29PMCID: PMC3381065CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Silberstein S, Mathew N, Saper J, for the Botox Migraine Clinical Research Group. Botulinum toxin a as a migraine preventive treatment. Headache. 2000;40:445–50.CrossRefPubMedGoogle Scholar
  15. 15.
    Tepper D, Traduzido por Marcelo MV. Onabotulinum A (Toxina OnabotulÃnica Do Tipo A, Botox®). Headache. 2014;54(4):791–2.CrossRefGoogle Scholar
  16. 16.
    Barton PM, Schultz GR, Jarrell JF, Becker WJ. A flexible format interdisciplinary treatment and rehabilitation program for chronic daily headache: patient clinical features, resource utilization and outcomes. Headache. 2014;54(8):1320–36.CrossRefPubMedGoogle Scholar
  17. 17.
    Jensen R. Diagnosis, epidemiology, and impact of tension-type headache. Curr Pain Headache Rep. 2003;7(6):455–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Verhagen AP. Lack of benefit for prophylactic drugs of tension-type headache in adults: a systematic review. Fam Pract. 2010;27(2):151–65.CrossRefPubMedGoogle Scholar
  19. 19.
    Jackson JL, Shimeall W, Sessums L, DeZee KJ, Becher D, Diemer M, Berbano E, O'Malley PG. Tricyclic antidepressants and headaches: systematic review and meta-analysis. BMJ. 2010;341:c5222.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Cohen GL. Protriptyline, chronic tension-type headaches, and weight loss in women. Headache. 1997;37(7):433–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Saper JR. Chronic daily headache: transformational migraine, chronic migraine, and related disorders. Curr Neurol Neurosci Rep. 2008;8(2):100–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Holroyd KA, Labus JS, Carlson B. Moderation and mediation in the psychological and drug treatment of chronic tension-type headache: the role of disorder severity and psychiatric comorbidity. Pain. 2009;143(3):213–22.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Tella BA, Unubum EV, Danesi MA. The effect of tens on selected symptoms in the management of patients with chronic tension type headache: a preliminary study. Nig Q J Hosp Med. 2008;18(1):25–9.PubMedGoogle Scholar
  24. 24.
    Espí-López GV, Arnal-Gómez A, Arbós-Berenguer T, González ÁAL, Vicente-Herrero T. Effectiveness of physical therapy in patients with tension-type headache: literature review. J Jpn Phys Ther Assoc. 2014;17(1):31–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Karadas O, Gül HL, İnan LE. Lidocaine injection of pericranial myofascial trigger points in the treatment of frequent episodic tension-type headache. J Headache Pain. 2013;14:44.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Linde K. Acupuncture for the prevention of tension-type headache. Chichester, UK: Wiley. John Wiley & Sons, Ltd; 2016.Google Scholar
  27. 27.
    Dodick D. Hemicrania continua: diagnostic criteria and nosologic status. Cephalalgia. 2015;21(9):874–7.Google Scholar
  28. 28.
    Peres MFP, Silberstein SD, Nahmias S, Shechter AL, Youssef I, Rozen TD, Young WB. Hemicrania continua is not that rare. Neurology. 2001;57(6):948–51.CrossRefPubMedGoogle Scholar
  29. 29.
    Rozen TD. Melatonin responsive hemicrania continua. Headache. 2006;46(7):1203–4.CrossRefPubMedGoogle Scholar
  30. 30.
    Peres MF, Silberstein SD. Hemicrania continua responds to cyclooxygenase-2 inhibitors. Headache. 2002;42(6):530–1.CrossRefPubMedGoogle Scholar
  31. 31.
    Schwedt TJ, Dodick DW, Hentz J, Trentman TL, Zimmerman RS. Occipital nerve stimulation for chronic headache—long-term safety and efficacy. Cephalalgia. 2007;27(2):153–7.CrossRefPubMedGoogle Scholar
  32. 32.
    Camarda C, Camarda R, Monastero R. Chronic paroxysmal hemicrania and hemicrania continua responding to topiramate: two case reports. Clin Neurol Neurosurg. 2008;110(1):88–91.CrossRefPubMedGoogle Scholar
  33. 33.
    Burns B, Watkins L, Goadsby PJ. Treatment of hemicrania continua by occipital nerve stimulation with a bion device: long-term follow-up of a crossover study. Lancet Neurol. 2008;7(11):1001–12.CrossRefPubMedGoogle Scholar
  34. 34.
    Garza I, Cutrer F. Pain relief and persistence of dysautonomic features in a patient with hemicrania continua responsive to botulinum toxin type a. Cephalalgia. 2009;30:500–3.Google Scholar
  35. 35.
    Obermann M, Holle D, Naegel S, Burmeister J, Diener H-C. Pharmacotherapy options for cluster headache. Expert Opin Pharmacother. 2015;16(8):1177–84.CrossRefPubMedGoogle Scholar
  36. 36.
    Ãzge A. Chronic daily headache in the elderly. Curr Pain Headache Rep. 2013;17:12.Google Scholar
  37. 37.
    May A, Leone M, Áfra J, Linde M, Sándor PS, Evers S, Goadsby PJ. EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias. Eur J Neurol. 2006;13(10):1066–77.CrossRefPubMedGoogle Scholar
  38. 38.
    Becker WJ. Cluster headache: conventional pharmacological management. Headache. 2013;53(7):1191–6.CrossRefPubMedGoogle Scholar
  39. 39.
    Cohen AS, Burns B, Goadsby PJ. High-flow oxygen for treatment of cluster headache. JAMA. 2009;302(22):2451.CrossRefPubMedGoogle Scholar
  40. 40.
    Law S, Derry S, Andrew Moore R. Triptans for acute cluster headache. Cochrane Database Syst Rev. 2010;7:CD008042.Google Scholar
  41. 41.
    Ekbom K, Je H. Cluster headache: aetiology, diagnosis and management. Headache. 2003;43(3):307–8.CrossRefGoogle Scholar
  42. 42.
    Dodick DW, Capobianco DJ. Treatment and management of cluster headache. Curr Pain Headache Rep. 2001;5(1):83–91.CrossRefPubMedGoogle Scholar
  43. 43.
    Leone M, D'Amico D, Frediani F, Moschiano F, Grazzi L, Attanasio A. Verapamil in the prophylaxis of episodic cluster headache: a double blinded study versus placebo. Neurology. 2000;54(6):1382–5.CrossRefPubMedGoogle Scholar
  44. 44.
    Goadsby PJ, Cittadini E, Burns B, Cohen AS. Trigeminal autonomic cephalalgias: diagnostic and therapeutic developments. Curr Opin Neurol. 2008;21(3):323–30.CrossRefPubMedGoogle Scholar
  45. 45.
    Bussone G, Leone M, Peccarisi C, Micieli G, Granella F, Magri M, Manzoni Gc, Nappi G. Double blind comparison of lithium and verapamil in cluster headache prophylaxis. Headache. 1990;30(7):411–7.CrossRefPubMedGoogle Scholar
  46. 46.
    Nierenburg H, Newman LC. Update on new daily persistent headache. Curr Treat Options Neurol. 2016;18(6):25.CrossRefPubMedGoogle Scholar
  47. 47.
    Mack KJ. What incites new daily persistent headache in children? Pediatr Neurol. 2004;31:122–5.CrossRefPubMedGoogle Scholar
  48. 48.
    Sheikh HU. Approach to chronic daily headache. Curr Neurol Neurosci Rep. 2015;15(3):4.CrossRefPubMedGoogle Scholar
  49. 49.
    Rozen T. New daily persistent headache: an update. Curr Pain Headache Rep. 2014;18(7):431.CrossRefPubMedGoogle Scholar
  50. 50.
    Tepper D. New daily persistent headache. Headache. 2016;56(7):1249–50.CrossRefPubMedGoogle Scholar
  51. 51.
    Joshi SG, Mathew PG, Markley HG. New daily persistent headache and potential new therapeutic agents. Curr Neurol Neurosci Rep. 2014;14(2):425.CrossRefPubMedGoogle Scholar
  52. 52.
    San-Emeterio EP, Hurlé MA. Modulation of brain apoptosis-related proteins by the opioid antagonist naltrexone in mice. Neurosci Lett. 2006;403:276–9.CrossRefPubMedGoogle Scholar
  53. 53.
    Chiappedi M, Mensi MM, Termine C, Balottin U. Psychological therapy in adolescents with chronic daily headache. Curr Pain Headache Rep. 2015;20:1.Google Scholar
  54. 54.
    Saper JR, Dodick D, Gladstone JP. Management of chronic daily headache: challenges in clinical practice. Headache. 2005;45(S1):S74–85.CrossRefPubMedGoogle Scholar
  55. 55.
    Eccleston C, Fisher E, Craig L, Duggan GB, Rosser BA, Keogh E. Psychological therapies (internet-delivered) for the management of chronic pain in adults. Cochrane Database Syst Rev. 2014;2:CD010152.Google Scholar
  56. 56.
    Martin PR, Forsyth MR, Reece J. Cognitive-behavioral therapy versus temporal pulse amplitude biofeedback training for recurrent headache. Behav Ther. 2007;38(4):350–63.CrossRefPubMedGoogle Scholar
  57. 57.
    Marcus DA, Scharff L, Mercer S, Turk DC. Nonpharmacological treatment for migraine: incremental utility of physical therapy with relaxation and thermal biofeedback. Cephalalgia. 1998;18(5):266–72.CrossRefPubMedGoogle Scholar
  58. 58.
    Glauser J. Assessment and management of migraine headaches–Primary care reports–Oct 01, 2012. Emergency medicine reports, 2012.Google Scholar
  59. 59.
    Garza I, Swanson JW. Prophylaxis of migraine. Neuropsychiatr Dis Treat. 2006;2(3):281–91.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Tzu-Hsien L. Neural plasticity in common forms of chronic headache. Neural Plast. 2015;2015:205985.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • Shweta Teckchandani
    • 1
  • Robert Cowan
    • 2
  1. 1.Department of Neurology, Stanford Headache and Facial Pain ClinicStanford Hospital and ClinicsPalo AltoUSA
  2. 2.Department of Neurology and Neurological Sciences, Stanford Headache and Facial Pain ClinicStanford School of MedicineStanfordUSA

Personalised recommendations